REGISTER
What Do 8-Year ADAURA Data Mean for Adjuvant Osimertinib? | Roy S. Herbst at WCLC 2026
At WCLC 2026, Prof. Roy S. Herbst reviews the eight-year ADAURA update on adjuvant osimertinib for resected EGFR-mutant NSCLC, focusing on long-term and subgroup outcomes, insights beyond the five-year analysis, treatment duration, and the role of measurable residual disease in postoperative treatment personalization.

This WCLC 2026 interview with Prof. Roy S. Herbst reviews the eight-year ADAURA update and its implications for adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.

Organized by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer (WCLC) brings together clinicians, researchers, nurses, and other thoracic oncology professionals to share major advances in lung cancer research and clinical care. WCLC 2026 took place in Seoul, Republic of Korea, from September 12 to 15.

Prof. Roy S. Herbst is Director of Dartmouth Cancer Center and Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth. Prof. Herbst’s research focuses on targeted therapy, immunotherapy, and biomarker-guided precision treatment for lung cancer.

Key highlights from this clip:

● Key findings from the exploratory eight-year ADAURA update

● Long-term outcomes following three years of adjuvant osimertinib

● Subgroup findings across stage IB–IIIA EGFR-mutant NSCLC

● The additional insights gained beyond the five-year overall survival analysis

● The optimal duration of adjuvant EGFR-targeted therapy

● MRD-guided personalization of postoperative treatment

This video is intended for medical education and professional discussion.

0
0
Loading